Gapping down
In reaction to disappointing earnings/guidance:
- N/A
Other news:
- MIST -72% (announces top-line results from Phase 3 NODE-301 trial of etripamil for PSVT misses primary endpoint)
- NYMT -35% (suspends dividends; notifies financing counterparties that it does not expect to fund existing and anticipated future margin calls)
- VXX -15.16% (falling with Futures rising in pre-mkt)
- LC -1% (says "vigilantly" monitoring performance)
Analyst comments:
- VSH -1% (downgraded to Underperform at Exane BNP Paribas)